Suzhou Basecare Medical Corp. Ltd. Class H (2170) AI Stock Analysis

• Market Cap: HK$774.08M
• Dividend Yield: N/A
• Average Volume (3M): 66.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: 41.62%
• EPS Growth: -22.27%
• Country: HK
• Employees: 497
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): -0.94
• Shares Outstanding: 82,713,840
• 10 Day Avg. Volume: 74,100
• 30 Day Avg. Volume: 66,466
• PEG Ratio: -0.12
• Price to Book (P/B): 0.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: ―

Suzhou Basecare Medical Corp. Ltd. demonstrates strong revenue growth but faces significant challenges with profitability and cash flow generation. The high leverage adds financial risk, while the technical indicators suggest mixed momentum with short-term bearishness. Valuation remains unattractive due to negative earnings and lack of dividends. Overall, the stock's potential is tempered by the need for improved operational efficiency and financial stability.

Suzhou Basecare Medical Corp. Ltd. Class H Business Overview & Revenue Model

Company Description

Suzhou Basecare Medical Corp. Ltd. Class H (2170) is a leading biotechnology firm specializing in the innovative development and commercialization of genetic testing solutions. The company operates primarily in the healthcare and biotechnology sectors, focusing on providing advanced prenatal and reproductive health testing services. Its core products include non-invasive prenatal testing (NIPT) kits and genetic testing services aimed at early detection and diagnosis of genetic disorders, contributing to improved health outcomes for patients.

How the Company Makes Money

Suzhou Basecare Medical Corp. Ltd. generates its revenue through the sale of its genetic testing products and services. The primary revenue streams include the sale of non-invasive prenatal testing (NIPT) kits and the provision of comprehensive genetic testing services to hospitals, clinics, and healthcare providers. The company also engages in strategic partnerships and collaborations with healthcare institutions and research organizations to expand its market reach and enhance its product offerings. Additionally, Suzhou Basecare may receive regulatory approvals and certifications that facilitate its entry into new markets, thus contributing to its earnings growth.

Suzhou Basecare Medical Corp. Ltd. Class H Financial Statement Overview

Summary

Suzhou Basecare Medical Corp. Ltd. exhibits robust revenue growth, driven by increased sales, however, it struggles with profitability due to high operating costs. The balance sheet indicates a sound equity base but is offset by high leverage, posing risks in financial stability. Cash flow generation remains a critical challenge, with persistent operational cash deficits undermining financial resilience. Overall, while the company shows promising growth prospects, improving operational efficiency and managing leverage are essential for enhancing financial health.

Income Statement

The company shows strong revenue growth with a consistent increase in total revenue over the years, indicating solid sales expansion. However, the net profit margin remains negative due to high operating expenses, impacting overall profitability. The gross profit margin is healthy, suggesting effective cost management in production, but the negative EBIT and EBITDA margins highlight ongoing challenges in operating efficiency.

Balance Sheet

The balance sheet reflects a stable equity base with a solid equity ratio, indicating strong capital structure. However, the high debt-to-equity ratio suggests potential leverage risk. The positive cash and short-term investments position bolsters liquidity, yet the negative net income limits return on equity, which remains a concern for investors.

Cash Flow

The cash flow statement shows consistent negative operating cash flow, raising concerns about the company's ability to generate cash from its core operations. The free cash flow position is improving, yet still negative, highlighting challenges in sustaining growth without external financing. The inability to convert operating cash flow to net income efficiently is a key area that needs attention.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	299.11M	207.98M	140.90M	107.30M	81.11M
Gross Profit	136.22M	91.35M	59.53M	51.15M	27.71M
EBITDA	-253.30M	-174.14M	-117.73M	-118.88M	-873.32M
Net Income	-237.03M	-191.69M	-123.16M	-143.65M	-877.05M
Balance Sheet
Total Assets	1.67B	1.90B	1.78B	1.80B	350.30M
Cash, Cash Equivalents and Short-Term Investments	684.63M	945.71M	1.33B	1.52B	192.32M
Total Debt	328.42M	281.92M	75.54M	48.57M	31.47M
Total Liabilities	527.47M	499.98M	188.33M	85.85M	68.96M
Stockholders Equity	1.14B	1.40B	1.59B	1.72B	281.33M
Cash Flow
Free Cash Flow	-322.41M	-371.44M	-317.52M	-234.71M	-72.38M
Operating Cash Flow	-229.12M	-267.23M	-188.77M	-197.85M	-64.29M
Investing Cash Flow	-181.19M	-324.81M	-88.70M	-56.60M	33.53M
Financing Cash Flow	33.78M	190.55M	23.51M	1.60B	207.47M

Suzhou Basecare Medical Corp. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2170, the sentiment is Negative. The current price of 2.83 is below the 20-day moving average (MA) of 2.91, below the 50-day MA of 2.96, and below the 200-day MA of 2.84, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.55 is Neutral, neither overbought nor oversold. The STOCH value of 31.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2170.

Suzhou Basecare Medical Corp. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$15.14B	5.55	-7.43%	4.45%	11.60%	-21.06%
2216	52 Neutral	HK$1.09B	―	-8.64%	―	-20.99%	45.74%
9996	51 Neutral	HK$4.27B	―	-10.43%	―	36.76%	42.89%
2170	50 Neutral	HK$774.08M	―	-18.64%	―	41.62%	-22.27%
2500	50 Neutral	HK$1.16B	―	-27.82%	―	-6.12%	0.43%
2160	47 Neutral	HK$2.12B	―	-2.19%	―	5.32%	89.43%

Suzhou Basecare Medical Corp. Ltd. Class H Corporate Events

Suzhou Basecare Medical Updates Nomination Committee for Governance Compliance

Suzhou Basecare Medical Corp. Ltd. announced changes to its Nomination Committee to align with the revised Corporate Governance Code effective from July 1, 2025. The appointment of Ms. Jiang Junchao and Dr. Yeung Shu Biu William as new members is expected to enhance the company’s governance structure and compliance with regulatory requirements.

Suzhou Basecare Medical Enhances Governance with New Nomination Committee

Suzhou Basecare Medical Corporation Limited has established a Nomination Committee as a specialized body under its Board to oversee the selection of candidates for directors and senior management positions. This move is designed to improve the company’s corporate governance by ensuring a well-structured and rationalized board composition, which is expected to positively impact its operational efficiency and strategic decision-making.

Suzhou Basecare Medical Announces AGM and Shareholder Meeting Results

Suzhou Basecare Medical Corp. Ltd. announced the poll results of its 2024 Annual General Meeting and the 2025 First Class Meetings for various shareholders. While most resolutions were passed, a resolution at the H Shareholders Class Meeting was not approved. The meetings were conducted in compliance with relevant laws and regulations, and the results are considered lawful and valid. This announcement reflects the company’s ongoing governance processes and may impact its shareholder relations and strategic decisions moving forward.

Suzhou Basecare Medical Announces 2024 AGM with Key Resolutions

Suzhou Basecare Medical Corporation Limited has announced its 2024 Annual General Meeting (AGM) scheduled for June 5, 2025, where shareholders will consider and approve various resolutions, including financial reports, profit distribution plans, and the re-appointment of KPMG as the auditor. The AGM will also address the issuance of additional shares and amendments to the Articles of Association, reflecting the company’s strategic initiatives to enhance its operational and financial framework.

Suzhou Basecare Medical Announces 2025 Shareholders Meeting to Amend Articles

Suzhou Basecare Medical Corp. Ltd. has announced the 2025 first class meeting for holders of domestic shares and unlisted foreign shares, scheduled for June 5, 2025. The meeting aims to consider and approve proposed amendments to the Articles of Association, reflecting the company’s ongoing efforts to refine its governance structure. The outcome of this meeting could have significant implications for the company’s operational framework and its stakeholders.

Suzhou Basecare Medical Announces 2025 H Shares Meeting

Suzhou Basecare Medical Corporation Limited has announced the convening of its 2025 first class meeting for holders of H shares, scheduled for June 5, 2025. The meeting will address a special resolution to amend the Articles of Association, which could impact the company’s governance and operational structure. The results of the meeting will be published on the company’s and Hong Kong Exchanges’ websites, providing transparency to stakeholders.

Suzhou Basecare Receives Approval for Home Sperm Quality Analyzer

Suzhou Basecare Medical Corporation Limited has received approval from the Jiangsu Medical Products Administration for its portable sperm quality analyzer, a device designed for home use to assess male fertility. This approval marks a significant step in the company’s expansion from professional medical institutions to general consumer applications, potentially broadening its market reach and enhancing its industry positioning.